Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05411237 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma

StatusNot Yet Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Dec 2026 to Sep 2029
    • Start date: Feb 2026 to Sep 2026
    • Study completion date: Nov 2027 to Sep 2030
    v11
  2. Primary completion date: Mar 2028 to Dec 2026
    • Start date: Sep 15, 2025 to Feb 2026
    • Study completion date: Dec 2029 to Nov 2027
    v10
  3. Start date: Mar 15, 2025 to Sep 15, 2025v9
  4. Start date: Dec 15, 2024 to Mar 15, 2025
    • Primary completion date: Dec 2027 to Mar 2028
    • Study completion date: Sep 2028 to Dec 2029
    v8
  5. Start date: Mar 15, 2024 to Dec 15, 2024v7
Show 5 earlier versionsHide 5 earlier versions
  1. Re-verified, no change to tracked fieldsv6
  2. Start date: Jun 2023 to Mar 15, 2024v5
  3. Start date: Dec 2022 to Jun 2023v4
  4. Eligibility criteria revisedv3
  5. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is being done to determine if two different anti-cancer drugs, paclitaxel (PTX) and pegylated liposomal doxorubicin (PLD) have similar effects on treating Kaposi Sarcoma (KS) in people living with HIV (human immunodeficiency virus) in sub-Saharan Africa. Patients with HIV-related KS will receive either PTX or PLD once every 3 weeks for a total of six cycles.
Trial Details
NCT Number NCT05411237
Lead Sponsor AIDS Malignancy Consortium
Collaborators: National Cancer Institute (NCI)
Conditions
(from sponsor)		 Kaposi Sarcoma, HIV-1-infection, AIDS-related Kaposi Sarcoma
Related terms Acquired Immunodeficiency Syndrome, AIDS-related Kaposi sarcoma, Sarcoma, Kaposi
Enrollment 130 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov